8-K
Axogen, Inc. (AXGN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2025
AXOGEN, INC.
(Exact Name of Registrant as Specified in Charter)
Minnesota
(State or Other Jurisdiction of
Incorporation or Organization)
001-36046
(Commission File Number)
41-1301878
(I.R.S. Employer Identification No.)
13631 Progress Boulevard, Suite 400 Alachua, Florida
(Address of principal executive offices)
32615
(Zip Code)
(386) 462-6800
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | AXGN | The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On October 29, 2025, Axogen, Inc. (the “Company”) issued a press release announcing its third quarter 2025 financial results. A copy of the press release is furnished as Exhibit 99.1.
The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 7.01 Regulation FD Disclosure
On October 29, 2025, the Company posted a third quarter 2025 financial results presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the financial results presentation from time to time in conversation with analysts, investors, and others. A copy of the presentation is furnished as Exhibit 99.2.
The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Axogen Inc. Earnings Press Release, dated October 29, 2025 |
| 99.2 | Axogen Inc. Third Quarter Financial Results Presentation, dated October 29, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AXOGEN, INC. | ||
|---|---|---|
| Dated: October 29, 2025 | By: | /s/ Marc Began |
| Marc Began | ||
| Executive Vice President, General Counsel and Chief Compliance Officer |
Document
Exhibit 99.1
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million
ALACHUA and TAMPA, FL – October 29, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025.
Third Quarter Financial Results
•Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a 6.0% increase over the second quarter of 2025.
•For the third quarter of 2025, gross margin was 76.6%, up from 74.9% for the third quarter of 2024, and up from 74.2% in the second quarter of 2025.
•Net income for the quarter was $0.7 million, or $0.01 per share, compared to a Net loss of $1.9 million, or $0.04 per share for the third quarter of 2024.
•Adjusted net income for the quarter was $6.1 million, or $0.12 per share, compared to $3.1 million, or $0.07 per share, for the third quarter of 2024.
•Adjusted EBITDA was $9.2 million for the quarter, compared to $6.5 million for the third quarter of 2024.
•The balance of cash and cash equivalents, restricted cash, and investments at September 30, 2025, was $39.8 million, as compared to a balance of $39.5 million at December 31, 2024, an increase of $0.3 million. Cash and cash equivalents, restricted cash, and investments increased $3.9 million during the third quarter of 2025.
“Our third quarter performance reflects the continued maturation of the peripheral nerve repair market, with revenue growing 23.5% to $60.1 million and adjusted EBITDA of $9.2 million as we scale our commercial operations,” commented Michael Dale, CEO and Director of Axogen, Inc. “New position statements from AAHS and ASRM, together with AAOMS guidelines recognizing nerve allografts as standard medical practice, and the addition of 1.1 million additional covered lives, validate our ongoing market development strategy. With double-digit growth across all markets and the expected completion of our Avance® Nerve Graft BLA in December, we’re advancing our mission to make peripheral nerve repair an expected standard of care.”
Summary of Business Highlights
•Third quarter 2025 revenue growth was broad-based, including double-digit growth from third quarter 2024 in all markets, which includes Extremities, Oral Maxillofacial & Head and Neck, and Breast.
•The American Association of Hand Surgery (“AAHS”) and the American Society for Reconstructive Microsurgery (“ASRM”) released official position statements recognizing nerve allograft as a standard medical practice option for the treatment of peripheral nerve defects during the third quarter 2025. Including the previously released clinical practice guidelines from the American Association of Oral and Maxillofacial Surgeons (“AAOMS”), the number of societies with positional statements or clinical practice guidelines increased to three.
•Expanded coverage and reimbursement for nerve repair for peripheral nerve injuries using synthetic conduits or allografts, increasing the total number of new lives covered in 2025 to approximately 18.1 million and bringing coverage amongst commercial payers to more than 64%.
•The U.S. Food and Drug Administration (“FDA”) accepted the filing of the Company’s Biologics License Application (“BLA”) for Avance® Nerve Graft on November 1, 2024, and assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of September 5, 2025, and on August 22, 2025 extended the PDUFA goal date to December 5, 2025. FDA approval of the BLA for Avance® Nerve Graft is now anticipated by December 5, 2025.
2025 Financial Guidance
We are raising our revenue guidance to at least 19% growth, or $222.8 million for the full year. We continue to expect gross margin for the year to be in the range of 73% to 75%. This range reflects one-time costs, mainly related to an anticipated Avance® Nerve Graft BLA approval, which we expect will negatively impact gross margin by approximately 1%, or $2 million. Lastly, we reiterate that we expect to be net cash flow positive for the full year.
Conference Call
The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link.
Following the conference call, a replay will be available in the Investors section of the Company’s website at www.axogeninc.com under Investors.
About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine (pig) submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while minimizing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue healing. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea and several other countries.
For more information, visit www.axogeninc.com.
Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “priorities,” “objectives,” “targets,” “intends,” “plan(s),” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our business model optimization plans; market development strategies and objectives; our expectations around the potential positive impact on our business of the AAHS and ASRM releasing official position statements recognizing nerve allograft as a standard medical practice options for the treatment of nerve defects, as well as clinical practice guidelines from the AAOMS; our expectations around the potential positive impact on our business of expanded coverage and reimbursement for peripheral nerve injuries using synthetic conduits or allografts; our beliefs around the strengths and discipline of our commercial execution; our business purpose to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care; and our expectation of BLA approval in December 2025, as well as statements under the subheading “2025 Financial Guidance.” Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, potential disruptions from leadership transitions, global supply chain issues, record inflation, hospital staffing challenges, product development timelines, product potential, expected clinical enrollment timing and outcomes, regulatory processes and approvals, financial performance, sales growth, surgeon and product adoption rates, market awareness of our products, data validation processes, our visibility at and sponsorship of conferences and educational events, global business disruption from Russia’s invasion of Ukraine and related sanctions, recent geopolitical conflicts in the Middle East, the evolving macroeconomic environment (including financial market volatility), escalating geopolitical tensions and trade disputes with U.S. trading partners, potential impact of recent government actions and policies, including the One Big Beautiful Bill Act and the October 2025 U.S. government shutdown, on our business, tax position, and regulatory processes, as well as those risk factors described under Part I, Item 1A., “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2024 and other risks and uncertainties, which may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.
About Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further exclude noncash stock compensation expense, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Common Share - diluted which excludes noncash stock compensation expense from Net Income (Loss) and Net Income (Loss) Per Common Share - diluted. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.
We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.
| Contact:<br><br>Axogen, Inc.<br><br>InvestorRelations@axogeninc.com |
|---|
Axogen, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
| September 30,<br>2025 | December 31,<br>2024 | |||
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 23,902 | $ | 27,554 |
| Restricted cash | 4,000 | 6,000 | ||
| Investments | 11,889 | 5,928 | ||
| Accounts receivable, net of allowance for doubtful accounts of $1,075 and $788, respectively | 30,775 | 24,105 | ||
| Inventory | 40,581 | 33,183 | ||
| Prepaid expenses and other assets | 3,309 | 2,447 | ||
| Total current assets | 114,456 | 99,217 | ||
| Property and equipment, net | 82,374 | 84,667 | ||
| Operating lease right-of-use assets | 13,137 | 14,265 | ||
| Intangible assets, net | 6,433 | 5,579 | ||
| Total assets | $ | 216,400 | $ | 203,728 |
| Liabilities and shareholders’ equity | ||||
| Current liabilities: | ||||
| Accounts payable and accrued expenses | $ | 25,672 | $ | 28,641 |
| Current maturities of long-term lease obligations | 2,336 | 1,969 | ||
| Total current liabilities | 28,008 | 30,610 | ||
| Long-term debt, net of debt discount and financing fees | 48,162 | 47,496 | ||
| Long-term lease obligations | 17,416 | 19,221 | ||
| Debt derivative liabilities | 1,868 | 2,400 | ||
| Other long-term liabilities | 141 | 94 | ||
| Total liabilities | 95,595 | 99,821 | ||
| Shareholders’ equity: | ||||
| Common stock, $0.01 par value per share; 100,000,000 shares authorized; 46,117,283 and 44,148,836 shares issued and outstanding, respectively | 461 | 441 | ||
| Additional paid-in capital | 414,151 | 394,726 | ||
| Accumulated deficit | (293,807) | (291,260) | ||
| Total shareholders’ equity | 120,805 | 103,907 | ||
| Total liabilities and shareholders’ equity | $ | 216,400 | $ | 203,728 |
Axogen, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Nine Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
| September 30, 2025 | September 30, 2024 | September 30, 2025 | September 30, 2024 | |||||
| Revenues | $ | 60,082 | $ | 48,644 | $ | 165,304 | $ | 137,933 |
| Cost of goods sold | 14,089 | 12,206 | 42,360 | 33,531 | ||||
| Gross profit | 45,993 | 36,438 | 122,944 | 104,402 | ||||
| Costs and expenses: | ||||||||
| Sales and marketing | 25,680 | 18,924 | 70,529 | 58,437 | ||||
| Research and development | 7,565 | 6,996 | 20,509 | 21,063 | ||||
| General and administrative | 10,836 | 10,834 | 29,983 | 30,206 | ||||
| Total costs and expenses | 44,081 | 36,754 | 121,021 | 109,706 | ||||
| Income (loss) from operations | 1,912 | (316) | 1,923 | (5,304) | ||||
| Other income (expense): | ||||||||
| Investment income | 319 | 296 | 816 | 816 | ||||
| Rental income | — | 90 | — | 90 | ||||
| Interest expense | (1,757) | (1,893) | (5,984) | (6,405) | ||||
| Change in fair value of debt derivative liabilities | 209 | 13 | 531 | 542 | ||||
| Other income (expense), net | 25 | (48) | 167 | (153) | ||||
| Total other expense, net | (1,204) | (1,542) | (4,470) | (5,110) | ||||
| Net income (loss) | $ | 708 | $ | (1,858) | $ | (2,547) | $ | (10,414) |
| Weighted average common shares outstanding — basic | 46,494,598 | 43,882,110 | 45,905,069 | 43,610,481 | ||||
| Weighted average common shares outstanding — diluted | 49,088,436 | 43,882,110 | 45,905,069 | 43,610,481 | ||||
| Net income (loss) per common share — basic | $ | 0.02 | $ | (0.04) | $ | (0.06) | $ | (0.24) |
| Net income (loss) per common share — diluted | $ | 0.01 | $ | (0.04) | $ | (0.06) | $ | (0.24) |
Axogen, Inc.
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Nine Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| September 30, 2025 | September 30, 2024 | September 30, 2025 | September 30, 2024 | |||||||||
| Net income (loss) | $ | 708 | $ | (1,858) | $ | (2,547) | $ | (10,414) | ||||
| Depreciation and amortization expense | 1,730 | 1,719 | 5,248 | 5,034 | ||||||||
| Investment income | (319) | (296) | (816) | (816) | ||||||||
| Income tax (benefit) expense | (62) | 26 | 4 | 76 | ||||||||
| Interest expense | 1,757 | 1,893 | 5,984 | 6,405 | ||||||||
| EBITDA - non-GAAP | $ | 3,814 | $ | 1,484 | $ | 7,873 | $ | 285 | ||||
| EBITDA margin - non-GAAP | 6.3 | % | 3.1 | % | 4.8 | % | 0.2 | % | ||||
| Noncash stock-based compensation expense | 5,424 | 5,004 | 13,501 | 12,830 | ||||||||
| Adjusted EBITDA - non-GAAP | $ | 9,238 | $ | 6,488 | $ | 21,374 | $ | 13,115 | ||||
| Adjusted EBITDA margin - non-GAAP | 15.4 | % | 13.3 | % | 12.9 | % | 9.5 | % | ||||
| Net income (loss) | $ | 708 | $ | (1,858) | $ | (2,547) | $ | (10,414) | ||||
| Noncash stock-based compensation expense | 5,424 | 5,004 | 13,501 | 12,830 | ||||||||
| Adjusted net income - non-GAAP | $ | 6,132 | $ | 3,146 | $ | 10,954 | $ | 2,416 | ||||
| Weighted average common shares outstanding - diluted | 49,088,436 | 43,882,110 | 45,905,069 | 43,610,481 | ||||||||
| Net income (loss) per common share - diluted | $ | 0.01 | $ | (0.04) | $ | (0.06) | $ | (0.24) | ||||
| Noncash stock-based compensation expense | 0.11 | 0.11 | 0.29 | 0.29 | ||||||||
| Adjusted net income per common share - diluted - non-GAAP | $ | 0.12 | $ | 0.07 | $ | 0.24 | $ | 0.05 |
Axogen, Inc.
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(unaudited)
(in thousands, except share amounts)
| Common Stock | Additional Paid-in<br>Capital | Accumulated<br>Deficit | Total Shareholders'<br>Equity | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | ||||||||
| Three Months Ended September 30, 2025 | |||||||||
| Balance at June 30, 2025 | 45,765,290 | $ | 457 | $ | 406,334 | $ | (294,515) | $ | 112,276 |
| Net income | — | — | — | 708 | 708 | ||||
| Stock-based compensation | — | — | 5,424 | — | 5,424 | ||||
| Issuance of restricted and performance stock units | 81,925 | 1 | (1) | — | — | ||||
| Exercise of stock options | 270,068 | 3 | 2,394 | — | 2,397 | ||||
| Balance at September 30, 2025 | 46,117,283 | $ | 461 | $ | 414,151 | $ | (293,807) | $ | 120,805 |
| Nine Months Ended September 30, 2025 | |||||||||
| Balance at December 31, 2024 | 44,148,836 | $ | 441 | $ | 394,726 | $ | (291,260) | $ | 103,907 |
| Net loss | — | — | — | (2,547) | (2,547) | ||||
| Stock-based compensation | — | — | 13,501 | — | 13,501 | ||||
| Issuance of restricted and performance stock units | 1,301,062 | 13 | (13) | — | — | ||||
| Exercise of stock options and employee stock purchases under the ESPP | 667,385 | 7 | 5,937 | — | 5,944 | ||||
| Balance at September 30, 2025 | 46,117,283 | $ | 461 | $ | 414,151 | $ | (293,807) | $ | 120,805 |
| Three Months Ended September 30, 2024 | |||||||||
| Balance at June 30, 2024 | 43,824,738 | $ | 438 | $ | 385,101 | $ | (289,852) | $ | 95,687 |
| Net loss | — | — | — | (1,858) | (1,858) | ||||
| Stock-based compensation | — | — | 5,004 | — | 5,004 | ||||
| Issuance of restricted and performance stock units | 112,185 | 1 | (1) | — | — | ||||
| Exercise of stock options | 65,400 | 1 | 573 | — | 574 | ||||
| Balance at September 30, 2024 | 44,002,323 | $ | 440 | $ | 390,677 | $ | (291,710) | $ | 99,407 |
| Nine Months Ended September 30, 2024 | |||||||||
| December 31, 2023 | 43,124,496 | $ | 431 | $ | 376,530 | $ | (281,296) | $ | 95,665 |
| Net loss | — | — | — | (10,414) | (10,414) | ||||
| Stock-based compensation | — | — | 12,830 | — | 12,830 | ||||
| Issuance of restricted and performance stock units | 695,571 | 7 | (7) | — | — | ||||
| Exercise of stock options and employee stock purchases under the ESPP | 182,256 | 2 | 1,324 | — | 1,326 | ||||
| Balance at September 30, 2024 | 44,002,323 | $ | 440 | $ | 390,677 | $ | (291,710) | $ | 99,407 |
Axogen, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
| Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, 2025 | September 30, 2024 | |||
| Cash flows from operating activities: | ||||
| Net loss | $ | (2,547) | $ | (10,414) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 5,027 | 4,831 | ||
| Amortization of right-of-use assets | 294 | 889 | ||
| Amortization of intangible assets | 221 | 202 | ||
| Amortization of debt discount and deferred financing fees | 666 | 669 | ||
| Provision for bad debts | 358 | 604 | ||
| Change in fair value of debt derivative liabilities | (531) | (542) | ||
| Investment gains | (238) | (95) | ||
| Stock-based compensation | 13,501 | 12,830 | ||
| Change in operating assets and liabilities: | ||||
| Accounts receivable | (7,028) | (85) | ||
| Inventory | (7,398) | (6,343) | ||
| Prepaid expenses and other assets | (619) | 1,189 | ||
| Accounts payable and accrued expenses | (2,985) | (7,125) | ||
| Operating lease obligations | (833) | (1,303) | ||
| Cash paid for interest portion of financing lease obligations | (3) | (2) | ||
| Other long-term liabilities | (111) | 495 | ||
| Net cash used in operating activities | (2,226) | (4,200) | ||
| Cash flows from investing activities: | ||||
| Purchase of property and equipment | (2,498) | (2,431) | ||
| Purchase of investments | (13,723) | (5,773) | ||
| Proceeds from sale of investments | 8,000 | — | ||
| Cash payments for intangible assets | (1,138) | (1,280) | ||
| Net cash used in investing activities | (9,359) | (9,484) | ||
| Cash flows from financing activities: | ||||
| Cash paid for debt portion of financing lease obligations | (11) | (6) | ||
| Proceeds from exercise of stock options and ESPP stock purchases | 5,944 | 1,326 | ||
| Net cash provided by financing activities | 5,933 | 1,320 | ||
| Net decrease in cash and cash equivalents, and restricted cash | (5,652) | (12,364) | ||
| Cash and cash equivalents, and restricted cash, beginning of period | 33,554 | 37,026 | ||
| Cash and cash equivalents, and restricted cash, end of period | $ | 27,902 | $ | 24,662 |
axgnq32025earningsreleas
Q3 2025 Financial Results October 29, 2025 1
Disclaimer 2 Forward-looking Statements This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “priorities,” “objectives,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements related to: our expectation for regulatory approvals including approval of the BLA for Avance® by the FDA in December 2025; market development opportunities; and 2025 financial guidance, including revenue growth, cash and gross margins. Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, statements related to potential disruptions caused by leadership transitions, global supply chain issues, record inflation, hospital staffing issues, product development, product potential, expected clinical enrollment timing and outcomes, regulatory process and approvals, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, global business disruption caused by Russia’s invasion of Ukraine and related sanctions, recent geopolitical conflicts in the Middle East, potential impact of recent government actions and policies, including the One Big Beautiful Bill Act and the October 2025 U.S. government shutdown, on our business, tax position, and regulatory processes, as well as those risk factors described under Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K for the most recently ended fiscal year. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements. About Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, Adjusted EBITDA, which further excludes non-cash stock compensation expense, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Common Share -diluted which excludes noncash stock compensation expense from Net Income (Loss) and Net Income (Loss) Per Common Share - diluted, respectively. We also use the Operational Cashflow metric, which corresponds to Net change in cash, cash equivalents, restricted cash, and investments, less cashflow from issuance or repayment of long-term debt. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non- GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements.
3 Michael Dale President and Chief Executive Officer Q3 2025 Business Highlights
Agenda 4 Q3 2025 Financials and Guidance Lindsey Hartley, Chief Financial Officer Q&A Michael Dale, Lindsey Hartley, Jens Kemp, Chief Marketing Officer Rick Ditto, VP Global Health Economic, Reimbursement & Policy Q3 2025 Business Highlights Michael Dale, President and Chief Executive Officer
5 Growth • Q3 revenue increased to $60.1M, growing 23.5% YoY • Q3 reflected broad-based growth across the entire portfolio • Double-digit growth performance in all markets High Potential Accounts • YTD, HiPo accounts yielded approx. 64% of YoY revenue growth (vs 2025 66% goal) • YTD, HiPo accounts have yielded 19% YoY increase in average account productivity (vs 2025 21% goal) • 668 Active HiPo accounts in the first three quarters of 2025; an increase of 1.2% YoY Professional Education • Breast: ended Q3 with 22 specialists and 2 regional sales directors ("RSD") • Extremities: ended Q3 with 110 reps and 15 RSDs • OMF/H&N: ended Q3 with 4 market development managers Commercial Infrastructure • Breast: 62 surgeon pairs trained YTD (vs. 2025 75 target); 121 active programs in Q3 (+7% YoY); 281 procedures in Q3 (+20% YoY) • Extremities: 97 surgeons trained YTD; target 105 by YE • OMF/H&N: 57 surgeons trained YTD; exceeding target 45 by YE 2025 Q3 Key Metrics Update Q3 2025 Recent Business Highlights
6 Clinical Research • Level 1 study protocol for implant based neurotization • Avance® vs. Autograft evidence plan in mixed & motor nerves. • OMF/H&N clinical evidence plan Innovation • Therapeutic reconstruction • Ease of coaptation • Protection expansion Prostate Clinical & Market Development • AAHS and ASRM recognizes Avance® Nerve Graft as standard medical practice in Q3 • 339 peer-reviewed articles, +10 in Q3 • ~1.1M est. additional covered lives added in Q3; ~18.1M est. new lives YTD Standard of Care • 10 active clinical sites; +4 in Q3 • Procedures underway • Goal of 100 procedures by year-end • Clinical development team hired 2025 Q3 Key Metrics Update Q3 2025 Recent Business Highlights
Biologics License Application For Avance® Nerve Graft Anticipate FDA approval for Avance® Nerve Graft as a Biologic in the US on December 5, 2025. 7 Q3 2025 Update
8 Lindsey Hartley Chief Financial Officer Q3 2025 Financials and Guidance Discussion
Q3 2025 Financial Performance 9 Q3 Revenue ($ in millions) $48.6 $60.1 2024 2025 Revenue $30.0 $35.0 $40.0 $45.0 $50.0 $55.0 $60.0 $65.0 $70.0 Q3 Gross Margin % 74.9% 76.6% 2024 2025 Gross Margin % 73.0% 73.5% 74.0% 74.5% 75.0% 75.5% 76.0% 76.5% 77.0% +1.7% +23.5%
Q3 2025 Financial Performance Gaining operating leverage with topline growth ($ in millions) 10 Q3 2025 Q3 2024 YoY Change % Change as a % of Revenue Sales and marketing expenses $25.7 $18.9 35.7% 3.8% Research and development expenses 7.6 7.0 8.1% (1.8)% General and administrative expenses 10.8 10.8 —% (4.2)% Total costs and expenses $44.1 $36.8 19.9% (2.2)%
Q3 2025 Financial Performance ($ in millions, except per share data) 11 * Excludes stock-based compensation. See non-GAAP reconciliations included in Appendix. Q3 2025 Q3 2024 Net income (loss) $0.7 $(1.9) Diluted EPS $0.01 $(0.04) Adjusted net income* $6.1 $3.1 Adjusted Diluted EPS* $0.12 $0.07 Adjusted EBITDA* $9.2 $6.5 Adjusted EBITDA margin* 15.4% 13.3%
Q3 2025 Financial Performance Operating cash flow ($ in millions) 12 * Cash, cash equivalents, restricted cash, and investments. September 30, 2025 June 30, 2025 Change Operational cash* $39.8 $35.9 +$3.9
Raising Guidance for the Full-Year 2025 Revenue growth of at least 19%, or $222.8 million Gross margin of 73% - 75% Net cash flow positive* 13 * Net change in cash, cash equivalents, restricted cash, and investments.
Michael Dale President and Chief Executive Officer Jens Kemp Chief Marketing Officer Rick Ditto VP, Global Health Economics, Reimbursement & Policy 14 Lindsey Hartley Chief Financial Officer Q&A
Thank you
Appendix 16
17 Non-GAAP Reconciliations: Three Months Ended (in thousands, except share and per share amounts) September 30, 2025 September 30, 2024 Net income (loss) $ 708 $ (1,858) Depreciation and amortization expense 1,730 1,719 Investment income (319) (296) Income tax (benefit) expense (62) 26 Interest expense 1,757 1,893 EBITDA - non-GAAP $ 3,814 $ 1,484 EBITDA margin - non-GAAP 6.3 % 3.1 % Noncash stock-based compensation expense 5,424 5,004 Adjusted EBITDA - non-GAAP $ 9,238 $ 6,488 Adjusted EBITDA margin - non-GAAP 15.4 % 13.3 % Net income (loss) $ 708 $ (1,858) Noncash stock-based compensation expense 5,424 5,004 Adjusted net income - non-GAAP $ 6,132 $ 3,146 Weighted average common shares outstanding - diluted 49,088,436 43,882,110 Net income (loss) per common share - diluted $ 0.01 $ (0.04) Noncash stock-based compensation expense 0.11 0.11 Adjusted net income per common share - diluted - non-GAAP $ 0.12 $ 0.07
